Yuanta/P-Shrs CSI 300 2X ETF (00637L)

Overview

co.don AG, founded in 1993 and based in Teltow, Germany, has ceased its significant operations. Previously, this company made its mark in the biopharmaceutical industry, primarily focusing on the development, production, and marketing of products aimed at the regenerative treatment of articular cartilage defects and joint preservation. The company's operations spanned globally, aiming to address the needs of patients requiring cartilage repair and regeneration therapies.

Products and Services

Prior to ceasing its significant operations, co.don AG was involved in a specialized sector of the biopharmaceutical industry focusing on the following areas:

• Joint Preservation: The company developed treatments aimed at preserving joint functionality and delaying or preventing the onset of osteoarthritis. These treatments were designed to help maintain the health of joints, particularly those suffering from minor to moderate cartilage damage, with the goal of preventing further degeneration.
• Regenerative Treatment of Articular Cartilage Defects: co.don AG specialized in regenerative therapies for repairing articular cartilage defects. These products were intended for patients who had suffered cartilage damage due to injury or degenerative diseases, facilitating the growth of new cartilage cells to restore the damaged area. The approach was designed to offer an alternative to more invasive procedures, promoting natural healing processes within the body.